Vimian (Buy, TP: SEK55.00) - Healthy growth to continue in Q4e
We expect continued healthy growth in Q4 despite further muted growth in high-cost elective orthopaedic procedures in the US. We have likely factored in higher operating expenses for marketing and education than consensus. This is also the first quarter with low-margin iM3 in the books. We reiterate our BUY and SEK55 target price.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.